Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Capsugel to Acquire Bend Research

Published: Thursday, September 12, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
Enhances bioavailability expertise.

Capsugel and Bend Research have announced that they have entered into a definitive agreement for Capsugel to acquire Bend Research as part of its Dosage Form Solutions (DFS) business unit.

The acquisition provides Capsugel DFS an industry leading position in bioavailability enhancement with access to a premier suite of technologies to address customers’ most pressing formulation challenges for oral drug delivery.

Additionally, it brings the company a full range of modified and targeted release solutions to develop innovative new products for its customers.

“The Bend Research transaction highlights Capsugel’s commitment to investment and strategic growth since becoming a KKR portfolio company in the 2011 carve-out acquisition from Pfizer,” said Guido Driesen, President & CEO of Capsugel.

Driesen continued, “Capsugel and Bend Research share common foundations in science and engineering, with values centered on innovation, quality and customer service. We have been impressed by Bend Research’s people, achievements and technology for some time and are delighted to combine our two companies. Capsugel’s vision of being a leading provider of innovative dosage forms and solutions to its healthcare customers is significantly advanced by this transaction.”

Bend Research is a recognized industry leader in bioavailability enhancement, particularly through Spray-Dried Dispersion (SDD) formulation technology.

Their portfolio is supplemented by technologies to help advance compounds with a variety of delivery and development challenges, including solutions for modified release, inhalation delivery and biotherapeutic processing and formulation.

Bend Research complements Capsugel DFS’s existing customer offerings with a broad range of technologies and best-in-class capabilities that support new compound development and enable improved life cycle management for existing products across pharmaceutical and nutritional markets.

“We are ready to take Bend Research to the next level and the combination of our two companies is the best vehicle for helping us get there,” said Rod Ray, Ph.D., CEO of Bend Research.

Ray continued, “We will expand our industry-leading capability to meet low bioavailability formulation challenges; strengthen the global footprint to support customer partnerships around the world; and enhance our ability to scale-up and commercially manufacture the customer compounds we help formulate. We are excited to be a part of Capsugel’s future.”

“Our customers strive to bring improved products to market more quickly and seek new and innovative ways to overcome difficult formulation challenges,” added Amit Patel, President of Capsugel DFS.

Patel continued, “Capsugel DFS will support effective and accelerated product development needs from formulation feasibility to final commercial production through new and expanding technologies and capabilities.”

He concluded, “Bend Research brings the leadership, capabilities and assets necessary to deepen our distinctive customer offerings and will ultimately enhance benefits delivered to patients and consumers.”

The completion of this transaction is subject to customary closing conditions including approval from regulatory authorities, and is expected to occur within the next 30 days. Terms of the transaction were not disclosed.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Capsugel Unveils New Spray-Dried Dispersion Commercial Manufacturing Facility
Significantly expands the commercial manufacturing capability at its Bend, Ore. Site.
Thursday, July 02, 2015
Capsugel Extends Inhaled Biotherapeutics Delivery Capability to Phase 2 Clinical Trials
Company partnering with customers to expand the use of inhalation technologies to treat a wider range of diseases.
Thursday, May 07, 2015
Capsugel Awarded EXCiPACT™ Certifications
First hard capsule manufacturer to receive this important third-party recognition.
Wednesday, October 08, 2014
Capsugel and Cardax to Collaborate on Astaxanthin Products Development
Collaboration leverages Capsugel’s proprietary lipid-based technologies for potential development of consumer health products.
Thursday, August 21, 2014
Capsugel Expands Global Manufacturing for Finished Dosage Forms
DFS unit expands capabilities for hormonal, high-potency compounds.
Thursday, September 26, 2013
Capsugel Unveils Quality Control Laboratory
South Carolina based facility provides global center of excellence for the company.
Monday, December 10, 2012
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!